Presented by
Management Forum
Biotechnology for the Non-Biotechnologist Training Course
An ideal course for non-scientists and scientists who need to understand the basic theory, principles, techniques and potential of biotechnology.
★★★★★ "All of the speakers were very knowledgeable, well prepared and presented the topics in a structured ... more (52)"
9-11 July 2025
+ 10-14 November 2025 »
from £1599
- Format: Classroom, Live online
- CPD: 18 hours for your records
- Certificate of completion
Course overview
The importance of the biotech industry has increased significantly over recent years and biotech companies now dominate the new drug pipeline. The industry is gaining momentum and advancements in biomedical science and increased innovation hold vast potential for the growth of the biotech market.
This intensive course will provide an overview of how biotech products are being developed and manufactured, and discuss the scientific and regulatory environment. The interactive programme will cover the latest advances in regulation, including biosimilars and advanced therapies, and address the role and importance of patents within biotech, including what actually can be patented.
This course is part of our Biopharma training courses series which aims to provide up-to-date knowledge on industry best practices and regulations surrounding biopharmaceuticals.
Benefits of attending
- Gain an introduction to the fundamental principles of biotechnology
- Improve your understanding of the key techniques used by biotechnologists
- Understand the key regulatory considerations for biopharmaceuticals
- Discuss advances in regulation – biosimilars and advanced therapies
- Learn how to identify potential patents, and why and how they must be protected
Who should attend?
This course is ideal for non-scientists and scientists needing to understand the basic theory, principles, techniques and potential of biotechnology.
It will be relevant for anyone needing either an overview or refresher, particularly those working in:
- Quality assurance
- Regulatory affairs
- Legal and IP
- Business development
- Sales and marketing
- Engineering
- Finance
- Clinical
- Training
- Project management
This course will cover:
Introduction to biotechnology
- Historical perspective
- Diversity of biotechnology products
- Impact on society
- Product development overview
Introduction to molecular biology
- DNA, RNA, genes, plasmids and vectors
- Protein synthesis – transcription and translation
Re-expression of proteins
- Recombinant DNA techniques
- Monoclonal antibodies – from mouse to human
- Transgenic animals and plants
Development of production organisms
- Transfection
- Selection
- Preservation
Fermentation technology and large-scale production
- Types of fermenters
- Fermentation basics
- Modes of operation
- Process development
Process optimisation and scale-up
- Scale-up strategies
- Strain improvement
- Media improvement
- Process improvement
Analysis of biopharmaceuticals
- Biological activity
- Physicochemical characterisation
- Purity, impurities and contaminants
Formulation design of biopharmaceuticals
- Factors affecting degradation
- Choice of excipients
- Prolonging shelf life
Product recovery and purification
- Cell harvesting and removal
- Clarification – intracellular and extracellular proteins
- Chromatographic techniques
Process economics
- Drug development and bioprocess economics
- Optimising bioprocess economics
- Manufacturing make or buy
- Future manufacturing alternatives
Patenting biotech inventions
- What is a patent?
- What are the basic criteria for patentability?
- What can be patented?
- Can you patent genes, proteins, hybridomas, and stem cells?
Patent workshop
- How to recognise what is patentable
- Drafting claims to biotech inventions
- Maximising protection for an invention
- Understanding the examination process
- Enforcing patents
Regulatory considerations of biopharmaceuticals
- General principles
- Product quality and control
- Pre-clinical safety
Application of regulatory principles
- What do regulators want?
- Specifications
- Product characterisation
- Assessment of process change
- Comparability guidance and strategy
Advances in regulation: biosimilars
- Comparability, equivalence and biosimilarity
- Biosimilars guidance
- Guidance vs practice – a case study
Advances in regulation: advanced therapies
- Gene therapy
- Cell therapy
- Tissue-engineered products
9-11 Jul 2025
10-14 Nov 2025
Adekunle Onadipe
Pfizer Inc.
Dr Adekunle Onadipe is an Associate Research Fellow in Bioprocess R&D, Cell Line Development at Pfizer Inc. USA. He leads a group of scientists responsible for the construction, development and characterization of mammalian and microbial cell lines for biotherapeutics and vaccines production. His group is also involved in the scale-up of bioprocesses from bench top to pilot scale bioreactors and process development for the establishment of cell banks to support the manufacture of biopharmaceutical products for early phase clinical trials.
Kunle joined Pfizer Limited in the UK in 2005 in Discovery Biology with responsibility for optimizing cell culture processes for the production of cell-based assay reagents. Prior to this he worked for 15 years at Lonza Biologics plc., in Slough UK where, as a Principal Group Leader in cell culture process development, he was responsible for constructing and developing production mammalian cell lines and culture processes, subsequently transferring them to full-scale production for clinical trials.
A microbiologist by training, Kunle has been involved in the production of biopharmaceuticals for more than 30 years and has a broad experience of microbial and mammalian cell culture methods. He obtained his PhD in Microbiology from the University of Surrey, Guildford UK.
9-11 Jul 2025
Suzanne Aldington
Lonza
Dr Suzanne Aldington is a Senior Principal Scientist at Lonza Biologics.
She has spent 22 years at Lonza, working on purification process development, scale up and technology transfer to GMP manufacturing facilities within the Lonza network. She has also led process validation activities at the Slough site, working with multiple biopharmaceutical companies. She has supported many regulatory submissions and also on-site inspections by the FDA and other Health Agencies.
Her current role at Lonza is within the Global Process Development team, working on harmonisation of activities across the global network in particular relating to purification, as well as troubleshooting and mentoring.
Suzanne also spent some time at Orchard Therapeutics, a Cell and Gene Therapy company which focuses on treatments for rare genetic diseases. Whilst there, she led the cell process and viral vector MSAT teams, supporting several clinical stage projects at different CDMO sites, with oversight of process development, manufacturing activities and process performance qualification batches as well as MAA and BLA submissions.
A microbiologist by training, she has over 30 years’ experience in academia and in the biotechnology industry. She received a microbiology degree from Imperial College and a Ph.D in biochemical engineering from the University of Birmingham.
9-11 Jul 2025
10-14 Nov 2025
Philip Webber
Dehns
Dr. Philip Webber obtained his first degree from Cambridge University, UK (Natural Sciences, Genetics) and then carried out research on the regulation of brain-specific genes at Warwick University, UK, where he obtained his PhD.
He qualified as a UK Chartered Patent Attorney and European Patent Attorney with Dehns (formerly Frank B. Dehn & Co.) London and Oxford, and is now a partner in their Life Sciences Group. He has a worldwide client-base including clients from the UK, Scandinavia, the US and Japan. Amongst other things, his work involves the preparation and filing of patent applications in Europe and throughout the world; acting for his clients in opposition procedures at the European Patent Office; and searching for and advising his clients on the relevance of competitors’ patents. He is an active member of the Life Sciences Committee of the UK Chartered Institute of Patent Attorneys (CIPA). He has spoken at a number of European conferences and on BBC Radio on the patenting of biotech inventions, as well as publishing a number of papers in this area.
9-11 Jul 2025
10-14 Nov 2025
Philip Webber
Dehns
After obtaining a degree in Natural Sciences (Genetics) from Cambridge University (UK) and a PhD in molecular biology from Warwick University (UK), Philip joined Dehns in 1992. He is a qualified UK and European patent attorney, and a partner in Dehns’ Biotechnology and Life Sciences Group.
Philip’s work is largely with start-ups, small/medium size companies and universities with inventions in the pharmaceutical or biotechnological fields. He has over 30 years’ experience in dealing with the issues which are important to such entities, such as the financial constraints of start-ups, the need to develop IP strategies for a company’s products and the pressures upon academics to publish their work.
Philip’s work involves writing and filing patent applications, and getting them granted for his clients all around the world. He has particular expertise in obtaining European patents (including dealing with EPO Opposition and Appeal procedures) and US patents. He also provides advice on IP landscapes and Freedom to Operate (FTO) advice on competitors’ patents.
Using his background in molecular biology, Philip deals with patents and formulates IP strategies in all pharmaceutical and biotechnological fields, including recombinant DNA and protein products, antibodies, biosimilars, transgenic plants and animals, bioinformatics, stem cells, biofuels, diagnostics assays, therapeutic treatments, virology and vaccines.
Philip was a member of the Life Sciences Committee of the UK Chartered Institute of Patent Attorneys (CIPA) from 2001-2016. His work on that Committee included reviewing proposed changes to UK and EPO patent legislation, and keeping UK patent attorneys updated on changes to biotech patent law and practice worldwide.
9-11 Jul 2025
10-14 Nov 2025
Adrian Haines
Swedish Orphan Biovitrium SA (Sobi)
Dr Adrian Haines is a Senior Process Manager within MSAT at Sobi (Swedish Orphan Biovitrum). Adrian has extensive experience in generating mammalian cell lines suitable for the GMP production of biologics and is extensively involved in the scientific oversight of both upstream and downstream process development, and process characterisation studies prior to regulatory filings. He joined the company (then Novimmune, Switzerland, subsequently acquired by Sobi) in 2015 and prior to this he worked at Lonza Biologics in the UK working on projects to develop new technologies and processes for generating manufacturing cell lines. Before that he worked for ML Laboratories/Cobra Research developing UCOE technologies for the expression of proteins in mammalian cells and at Therexsys Ltd, developing antibody targeted gene therapies. Prior to this he worked at Celltech Research Ltd, generating radiolabelling and cross-linking technologies for antibodies. A biochemist by training, he has been involved in the protein chemistry and production of monoclonal antibodies ~30 years, starting with his PhD where he generated monoclonal antibodies (using hybridoma technology) for the diagnosis of prostate cancer. He received a biochemistry degree from Imperial College, London, and his PhD from St Thomas’ Hospital Medical School, University of London. He is currently based in the UK.
9-11 Jul 2025
10-14 Nov 2025
Robert Alvarez
Lonza Biologics Plc
After completing his degree in molecular biology at the University of Reading, Robert Alvarez has been at Lonza Biologics for 17 years, of which 14 were spent working in the product stability group and 2 as Head of Business Planning and Innovation within Analytical Services (AS). Most recently he has accepted a new role as Site Head of Digital Transformation spearheading Lonza’s digitilisation strategy. Within AS he was a Subject Matter Expert responsible for the design and implementation of forced degradation and formulation studies, directing stability programs for multiple products and establishing standards for stability, as well as supporting stakeholders and customers. As analytical lead for mAb and non‑mAb programs, he has provided technical and advisory support for CMC development of biopharmaceuticals from pre-clinical through to clinical phases, including successful BLA licence applications.
9-11 Jul 2025
10-14 Nov 2025
Rhydian Howells
ProPharma Group
Rhydian Howells, associate director of regulatory affairs at Diamond Pharma services a Propharma group company. 20 years’ experience in the industry, 10 years at a large contract manufacturer developing manufacturing processes and analytical offerings for biological products followed by 10 years in regulatory CMC roles supporting clients with clinical development and marketing authorisation activities for large molecules and advanced therapies.
10-14 Nov 2025
Mardon McFarlane
AAVantgarde Bio / Taxo Bio
Mardon McFarlane currently works as a Director of External Manufacturing for the gene therapy company AAVantgarde Bio. Mardon is a co-founder of a consultancy, Taxo Bioscience, that specialises in supporting pre-clinical and clinical stage biotech companies, by ensuring they make the correct, impactful decisions early in their journey to bring life-changing therapies to patients. Mardon specialises in the CMC aspect of drug discovery and has been involved in notable drug approvals during his 18+ years in the industry. His experience in the biotechnology sector started with biologics but over the last 11 years he has migrated to the cutting-edge sector of cell and gene therapy. Mardon’s career has been focused on the processing aspects of drug manufacture and has spanned process development, technology transfer, scale up and large-scale manufacturing. Mardon holds an MEng in Biochemical Engineering from University College London.
9-11 Jul 2025
10-14 Nov 2025
Lekan Daramola
LD BioConsulting
Lekan Daramola is an independent consultant who specialises in supporting biotech companies during the critical early drug development activities, enabling successful preclinical and clinical decisions as they develop new drugs for patients.
Lekan has extensive experience working in the biopharmaceutical industry, with over 26 years contribution to different areas of biologics drug development. Lekan’s experience spans lead drug molecule selection to regulatory submission. His expertise includes molecular biology, mammalian recombinant protein expression technologies, cell line development and early CMC support. In addition, he also has expertise in the development of novel drug modalities like nucleic acid drugs/vaccine (RNA, DNA) as well as AAV (viral vector) production platform development.
Prior to his current role, Lekan was a Senior Director at AstraZeneca, managing mammalian expression activities, the development of nucleic acid and AAV production capabilities to deliver preclinical and clinical drug development goals. Lekan hold a M.Sc. in Medical Microbiology from the University of Surrey.
NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:
- 30% off the 2nd delegate*
- 40% off the 3rd delegate*
- 50% off the 4th delegate*
Please contact us for pricing if you are interested in booking 5 or more delegates
9-11 July 2025
Classroom
Rembrandt Hotel
London
08:30-17:00 UK (London)
Course code 14946
Optional £300/€419/$479 per night
- GBP 2,199
- EUR 3,079
- USD 3,519
Limited places remaining
- 3 days classroom-based training
- Optional accommodation - 3 nights including breakfast, checking in the day before the course
- Meet presenters and fellow attendees in person
- Lunch and refreshments provided
- Download documentation and certification of completion
- Fair transfer and cancellation policy
Not ready to book yet?
for 7 days, no obligation
10-14 November 2025
Live online
12:00-17:00 UK (London) (UTC+00)
13:00-18:00 Paris (UTC+01)
07:00-12:00 New York (UTC-05)
Course code 15117
- GBP 1,599 1,899
- EUR 2,239 2,659
- USD 2,571 3,039
Until 06 Oct
- 5 sessions of live online training
- Browser-based, no download usually required
- See presenters and interact with fellow attendees
- Download documentation and certification of completion
- Fair transfer and cancellation policy
Not ready to book yet?
for 7 days, no obligation
* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price; and apply only when booking multiple delegates on the same date.
Reviews of IPI's Biotechnology for the Non-Biotechnologist training course
All of the speakers were very knowledgeable, well prepared and presented the topics in a structured and comprehensible manner. A session I thought would be rather arid turned out to be entertaining and instructive at the same time. The seminar gave a very complete overview of the topics.
Dec 2 2024
Max Hofferberth 
DSTL, Hoffmann LaRoche
Dec 2 2024
I wanted to get a good overview of biotechnology: history, development, science, processes, regulations and future and this goal was 100% fulfilled. All lecturers were highly competent in terms of content and style of presentation.
Andy Bossert
CQV Engineer, Lonza
Sep 25 2024
Content flow is well designed and good. [Parts I particularly liked were] process economy , Upstream and Downstream scale up.
Arindam Gupta 
Global Category Procurement Manager, Servier Monde
Sep 25 2024
Excellent, I am so please a colleague mentioned to IPI to me.
Julie Bailey 
CFO, ILC Therapeutics Ltd
Sep 27 2023
I thought all the speakers were excellent. You could tell that they all really knew there subject matter and were so passionate in the way they delivered the content. Special mention has to go to Adekunle - fantastic course leader and so knowledgeable and made the 3 days very interactive.
Mark Kalinowski
Chief Financial officer, Albumedix Ltd
Sep 27 2023
The course was good and it was a pleasure to learn from the speakers. I wanted to get an overview of research and development of drugs and pharmaceuticals. I think this was achieved.
Sarah Kanna 
Senior Legal Associate, Hevolution Foundation
Jun 26 2023
Very good
Jurgen Vercruysse 
Business Unit Manager Drug Product, Eurofins Amatsigroup
Dec 5 2022
It was great. All speakers presented well and were knowledgeable about the Industry/topic.
Shanell Burwell 
Compliance Manager Internal External Audits, Pfizer
Dec 5 2022
I have a masters in Biochemistry and have worked as a formulation scientist for 1 year so I wanted to gain more applied knowledge, and a broader understanding of the drug development process. I found the content of this webinar easy to understand and it was nice to have the information presented to me in an organised and coherent manner.
Samantha Martell
Scientist 1, Ipsen Biopharm
Sep 28 2022
All speakers were knowledgeable on their respective topics and could give explanations in detail. Overall I was satisfied with each given presentation... Personally, I enjoyed seeing the overview of product development from start to finish, and the background of the (GMP) regulations. Reasons for this is personal interest and relevance to my current job.
Christian Malonda 
Process Engineer, Janssen Biologics BV
Sep 28 2022
One of the best courses I attended because the target was clear and the execution met the expectations... The whole course was well integrated to give to non specialist an overview of everything.
Tomaso Guidi 
Head of Formulation and Process Development, Chiesi Farmaceutical SpA
Mar 7 2022
The level of detail and complexity was just right and I have learnt a lot and would certainly recommend this course to others. I thoroughly enjoyed the course.
Melanie Pires
Pharmaceutical Assessor, Medicines and Healthcare Products Regulatory Agency (MHRA)
Sep 28 2022
Very good content considering the target population, good compromise on the level of detail, very good material and excellent speakers
Francesca Usberti
Head of Pharmaceutical Development , CHIESI FARMACEUTICI SPA
Sep 28 2022
Positive and professional
Mauro Provezza
Site Manager, Bayer Cropscience SRL
Mar 7 2022
The webinar was very good overall with very comprehensive material and understandable throughout. The speakers were very knowledgeable and were open to questions and comments and answered them very professionally.
Tomas Orn Sigurbjornsson 
Sourcing Lead, Alvotech
Dec 1 2021
Excellent course with expert speakers. It is highly recommended to people who already have a background on life sciences.
Mary Malamatari
Assessor, Medicines and Healthcare Products Regulatory Agency (MHRA)
Dec 1 2021
Every speaker brought in their own experience and passion that should offer something for attendants from a variety of backgrounds and levels of detail, and certainly did for mine...Excellent content for somebody lacking a bio or chemistry background providing a clear and useful understanding of the building blocks that make up the biotech industry.
Patrick Helm
Sr. Associate Contract Management, Genmab B.V.
Sep 29 2021
The content was excellent and all presenters were clearly SMEs, who managed to explain much of the complex content in an understandable way.
Sunil Singh
Director, Regulink Ltd
Apr 14 2021
Excellent. Really enjoyed and learned a lot.
Anthony Barker
Regulatory Project Director , AstraZeneca
Dec 1 2021
I really enjoyed the course and I have already recommended it.
Paolo Gasbarrone
Principal scientist, Merck group
Apr 14 2021
The presentations were well prepared in general and I learned a lot.
Katja Pecjak 
Associate Director & QPPV, Billev farmacija vzhod d.o.o
Sep 30 2020
I felt like the three days flowed together really well, first giving a basic understanding of the biology side of these products, how they are made and then their uses.
Laura Jones
Regulatory CMC Manager, AstraZeneca
Sep 30 2020
Really interesting, and a great introduction to someone with little/no knowledge of biotechnology. Also great that it went from scientific processes through to industrial processes. Nicely laid out. Well worth the three days!
Jackie Knipe
IP Paralegal, ALBUMEDIX LTD
Apr 10 2019
Well-balanced set of topics – nothing of importance seems to have been left out. The perfect level of detail for me as a biotech program leader/manager with a non-biotech scientific background.
Sergio Freitas
Development Program Lead, Tillotts Pharma AG
Sep 25 2019
A good general introduction that managed to make this very technical subject matter understandable to those with little scientific background, or as a refresher to those who may have graduated many years previously.
Matthew Jordan
Imerys Minerals
Sep 25 2019
The course was comprehensive and the speakers were both subject matter experts and very good presenters. I really enjoyed the three days.
Linnea Elrington
VP, Head of HR, Silence Therapeutics
Sep 25 2019
I thought it was a really interesting overview of biotechnology, from the specific scientific processes all the way through to the industry trends. I appreciated the discussion of advantages/ disadvantages and challenges of various methods and the industry as a whole, as I think this added a lot of context. This was beneficial for me when I was trying to apply what I had learned in the day to my specific company's context.
Sian Gilfillan
Marketing and Communications Associate, Albumedix
Apr 10 2019
I wanted to learn the basics of biologicals research and establishment/characterization of MCB. I also wanted to learn more on biologics manufacture and registration/filing. All of this was accomplished.
Michael Vestling 
Regulatory and Quality Manager, INTERVACC AB
Apr 10 2019
I really appreciated the course and learned a lot.
Natacha Gonzalez
CMC Dossier & Compliance Specialist, Merck
Apr 10 2019
The content and presentation were very good.
Rutger Vandiest 
Sr Director - Head of Sales, Bavarian Nordic
Sep 26 2018
Excellent course – I learned a lot despite having worked as an in-house lawyer for a CMO for almost 5 years. The speakers were highly competent, engaged, knowledgable and able to answer all of my questions (and I had quite a few). Overall, a course I can highly recommend to other in-house lawyers.
Anna Damgaard Jensen 
Head of Legal , AOP Orphan Pharma
Sep 26 2018
The course is prepared to explain biotechnology in a very clear and complete way. It is intensive and you have to be focused to follow, but it's definitely worth the effort!
Roza Puzio
European Projects Manager, Atlanpole
Apr 25 2018
All speakers were excellent and explained complex ideas very well. Fantastic, applicable course, presented really well. Great refresher course on molecular biology.
Luisa Teixeira
Account Manager, Owen Mumford Ltd
Apr 25 2018
Very good with lots of content. Thank you!
Falk Neukirch 
CFO, Vita 34 AG
Apr 25 2018
Highly qualified speakers.
Merecedes Rodríguez Rojas 
Business Manager, CZ Veterinaria, S.A
Apr 25 2018
A good mix of speakers – the course was useful for me.
Oliver Dale
Senior Specialist, MSD
Apr 25 2018
Interesting course with good quality speakers.
Anna Sarao
Regulatory Affairs Project Manager, Servier
Apr 26 2017
Very positive opinion. Content very clear. Interaction with speakers was fruitful. Good to have each day a summary of what was learnt the day before.
Vanessa Brousset
Manager Europe, Galderma R&D
Apr 26 2017
Very good. Broad overview. Friendly audience
Jean-Paul Chappuis
Galderma International
Apr 26 2017
Speakers - well experienced. Content - well structured presentations
Lina Cacic 
Principal Advisor for Regulatory Affairs, Agency for Medicinal Products and Medical Devices of Croatia (HALMED)
Sep 27 2017
Very good.
Rabiea Abdullah
Senior Regulatory Specialist, MSD
Sep 27 2017
Well-structured training, clear presentations and explanations.
Oliver Jungmann
Global Head Drug Substance Technical Lead, F. Hoffmann-La Roche Ltd.
Sep 27 2017
Very good course, a bit condensed, very good speakers
Erik Andersen
Associate Director, Ferring Pharmaceuticals A/S
Apr 26 2017
Course covers biopharmaceutical aspects of biotechnology thoroughly. Good presenters
Patrick John Couzens
Patent Attorney, Société des Produits Nestlé S.A.
Sep 19 2016
An excellent course! Very informative both for beginners and as a refresher.
Sarah Norton
Senior Scientific Officer, Veterinary Medicines Directorate
Apr 27 2016
I liked the course and would recommend this to work colleagues
Anna Woźniak 
Valeant Sp. z o.o. Sp. j.
Apr 27 2016
Very comprehensive and intense. Mostly interested in the science and processes, less interested in patents.
David Cooke
Analytical Science Team Leader, Pfizer Ltd
Sep 19 2016
Course was very well outlined, prepared and presented
Isaac Hanania
LL.M., Boehringer Ingelheim RCV GmbH & Co KG
Sep 19 2016
I really enjoyed this course, it was detailed and interesting. Speakers were very well qualified and good presenters.
Jill Challis
Principal Consultant, NDA Regulatory Science Ltd
Sep 19 2016
Very well organised
Marjon van Dijk
Associate Consultant Chemistry, Manufacturing & Control, Kinesis Pharma B.V
Apr 27 2016
Intense but very interesting course that takes you back to the basis of biotechnology and also provides some inside in regulations
An van Hemelrijck
RA Consultant, PhaRA
Apr 27 2016
Good, useful, complicated
Nicolai Soberg-Hansen
Patent Administrator, Genmab A/S
United Kingdom
- Medicines and Healthcare Products Regulatory Agency (MHRA)
- FUJIFILM Diosynth Biotechnologies UK Limited
- --
- 42 Technology Ltd
- 4D Pharma Research Ltd
- AA Thornton & Co
- AbbVie
- Actavis Biologics Ltd
- Albumedix
- Albumedix Limited
- Albumedix Ltd
- Alere
- Alexion Pharma UK Ltd
- Alizyme Plc
- Allergan Limited
- Allergan UK Limited
- Alta Innovations Ltd
- AMGEN LTD
- Antisoma Research Ltd
- Apothecom Limited
- Aptuit (Edinburgh) Ltd
- Archimedes Pharma UK Limited
- AstraZeneca
- AstraZeneca R&D Charnwood
- AstraZeneca UK Ltd
- Avecia Biotechnology Ltd
- Avecia Ltd
- Bayer Healthcare
- Bayer plc
- Biogen
- Biogen Idec Ltd
- BioReliance Ltd
- Boehringer Ingelheim International GmbH
- Borealis Medical
- Breakthrough Properties
- Bristows LLP
- Canary Wharf Group
- Cancer Research UK
- Catalent Pharma Solutions
- CCLRC DARESBURY LABORATORY
- CELLTECH
- CHI
- CHIRON VACCINES
- Chugai Pharma Europe
- Clinigen Group PLC
- Covance
- Cyton Biosciences Ltd
- D Young & Co LLP
- Dermal Laboratories Ltd
- Eisai Limited
- Eli Lilly & Co Ltd
- Eli Lilly & Company Limited/Elanco Animal Health
- Eli Lilly & Company Ltd
- European Medicines Agency
- EUSA Pharma Ltd
- Ferring Controlled Therapeutics Ltd
- Freeline Therapeutics Limited
- French Trade Commission UBI France
- Fujifilm Kyowa Kirin Biologics
- Genzyme
- Genzyme Ltd
- Gilead Sciences International Ltd
- GILROY FILTRATION LTD
- GlaxoSmithKline
- GlaxoSmithKline Research & Development Ltd
- Gowling WLG
- Gowling WLG (UK) LLP
- Gregory Fryer Associates
- GSK
- Hospira UK Limited
- Icon Clinical Research
- Idis Limited
- IDIS LTD
- IHS Global Insight
- ILC Therapeutics Ltd
- Imerys Minerals
- IMS Health UK
- INVEST NORTHERN IRELAND
- Ipsen Biopharm
- Ipsen Biopharm Ltd
- IQVIA
- J A Kemp & Co
- Johnson Matthey PLC
- Kings College London
- KPMG
- Lallemand Animal Nutrition
- Leo Pharma
- Lonza Biologics PLC
- Lundsberg Consulting
- Medical Research Council
- Medicines and Healthcare Products Regulatory Agency (MHRA)
- Medicines and Healthcare Products Regulatory Authority
- MedImmune Ltd
- Melbourn Scientific Limited
- MERCK GENERICS UK LTD
- Merck Sharp & Dohme Ltd
- Mercury Pharmaceuticals Ltd
- MHRA
- Mitsubishi Tanabe Pharma Europe Ltd
- MSD
- Murex Biotech Ltd
- NCL Technology Ventures
- NDA Regulatory Science Ltd
- New Zealand Trade and Enterprise
- Novartis Pharmaceuticals UK Ltd
- O'MELVENY & MYERS
- Owen Mumford Ltd
- PANNONE & PARTNERS
- Parexel International Ltd
- Pfizer
- Pfizer Cambridge
- Pfizer Global Research & Development
- Pfizer Limited
- Pfizer Ltd
- Pfizer Uk Group Ltd
- Pfizer Uk Ltd
- Pharmedd Services Ltd
- Phillips Medisize
- Phillips-Medisize
- Precipio Consulting
- Probiotics International Ltd.
- Real Regulatory Ltd
- Reckitt Benckiser Healthcare (UK) Ltd
- Regulink Ltd
- Regulis Consulting Ltd
- Roche Products Ltd
- Rothamsted Research Ltd
- Sagentia Limited
- Sanofi Pasteur MSD Ltd
- Sekisui Diagnostics (UK) Ltd
- Shire Pharmaceutical Ltd
- Sidley Austin LLP
- Silence Therapeutics
- Smith & Nephew Extruded Films
- Stephen Griggs Ltd
- Stratagem IPM Limited
- Summit Therapeutics
- Takeda Cambridge Limited
- Taylor Vinters
- TEFEN EUROPE
- Teva UK Ltd
- The Immortality Project
- The Institute Of Cancer Research: Royal Cancer Hospital
- UCB Celltech
- UCB Celltech Limited
- UCB PHARMA LTD
- University of Southampton
- University of Surrey
- Vectura
- Vectura Group plc
- Veterinary Medicines Directorate
- WDA INTERNATIONAL
- WebBased Ltd
- WOOD MACKENZIE
- Wyeth Pharmaceuticals
- XENOVA LTD
Switzerland
- Abbott Products Operations AG
- Actelion Pharmaceutical Ltd
- Alexion Pharma EMEA GmbH
- Basel Area Business & Innovation
- BaselArea
- Bayer Consumer Care
- Bayer Consumer Care AG
- Bioeq AG
- DSM Nutrional Products Ltd
- Elanco
- Emergent Biosolutions
- F. Hoffman La Roche AG
- F. Hoffmann-La Roche
- F. Hoffmann-La Roche Ltd
- F. Hoffmann-La Roche Ltd.
- Ferring International Center SA
- Fresenius Kabi SwissBiosim
- Galderma
- Galderma SA
- GeNeuro
- Geneva Hospital (HUG)
- Haleon
- HALEON CH SARL
- Hoffmann LaRoche
- Ispettorato regionale dei Medicamenti
- Leman Consulting S.A.
- LimmaTech Biologics AG
- Lonza
- Lonza AG
- MCKIERNAN ASSOCIATES GMBH
- Merck
- Merck Serono SA
- MTPRO
- Nestle Skin Health - Galderma SA
- Novartis AG
- Novartis Animal Health Inc. C/O Elanco
- Novartis Pharma AG
- Novartis Vaccines & Diagnostics AG
- Octapharma AG
- PHF SA
- Rosenow Grob Schilling
- SERONO INTERNATIONAL SA
- Shire
- Société des Produits Nestlé S.A.
- Swedish Orphan Biovitrum AG
- Swiss Medic
- Swissmedic
- Switzerland Innovation Park Basel Area
- Syngenta Crop Protection Munchwilen AG
- TIllotts Pharma AG
- World Trade Organisation
France
- 3X Consultants
- ALEXION Europe SAS
- Atlanpole
- Bayer SAS
- Becton Dickinson
- Boehringer Ingelheim
- CHANEL PB
- Davidson Rhone Alpes
- Galderma International
- GALDERMA R & D
- Galderma R&D
- GALDERMA Recherche & Developpement
- Germain & Maureau
- HRA Pharma
- IFP Energies nouvelles
- Intervet Pharma R&D
- Ipsen Pharma SAS
- Laboratoires Galderma
- LFB Biomedicaments
- LFB Biotechnologies
- Merck Serono
- Merial
- Merial SAS
- Novartis Pharma SAS
- Novbartis - Centre de Biotechnologie
- QUINTILES SA
- Sanofi Chimie
- Sanofi Pasteur SA
- Sanofi-aventis Groupe
- Sanofi-Aventis R&D
- Sartorius Stedim Biotech
- Science Union SA
- SERONO
- Servier
- Servier Monde
- Societe HTL
- STALLERGENES GREER
- Technologie Servier
- Vetoquinol SA
Netherlands
- Akzo Nobel NV
- Amgen Europe BV
- Astellas BV
- Centocor BV
- Citryll BV
- DADA Consultancy
- De Vries & Metman
- EMA European Medicine Agency
- GENENCOR
- Genmab
- Genmab B.V
- Genmab B.V.
- Genmab BV
- Genzyme Europe BV
- Jadis Additiva bv
- Janssen Biologics BV
- Johnson&Johnson
- Kinesis Pharma
- Kinesis Pharma B.V
- Kinesis Pharma B.V.
- Kinesis Pharma BV
- Merck Sharp & Dohme
- Merus NV
- MSD Animal Health
- MSD/NV Organon
- Rabo Investments
- Rabobank Nederland
- SIMMONS & SIMMONS
- Tanatex Chemicals BV
- TargED Biopharmaceuticals B.V.
- TNO QUALITY OF LIFE
- Vintura
Denmark
- Albumedix Ltd
- Alk Abello A/S
- Ascendis Pharma A/S
- Bavarian Nordic
- BAVARIAN NORDIC A/S
- Danish Health and Medicines Authority
- DuPont Nutrition Biosciences ApS
- Ferring Pharmaceuticals A/S
- FUJIFILM
- FUJIFILM Diosynth Biotechnologies
- Genmab
- Genmab A/S
- Genmab AS
- Jusmedico Law Firm
- Leo Animal Health As
- LEO Pharma
- Leo Pharma A/S
- Maxygen ApS
- NNE A/S
- NNE Pharmaplan A/S
- Novo A/S
- Novo Nordisk A/S
- Novo Nordisk AS
- Novozymes A/S
- Servier
- SNIPR Biome
- SNIPR Biome APS
- Statens Serum Institut
- Symphogen
- Symphogen A/S
- Tarius A/S
Germany
- ABBOTT GmbH & Co KG
- Alfred E Tiefenbacher GmbH & Co KG
- Bayer AG
- Bayer Consumer Care AG
- Bayer Pharma AG
- BIO GENEVIX AG
- Boehringer Ingelheim
- Boehringer Ingelheim Animal Health GmbH
- Boehringer Ingelheim Pharma GmbH & Co KG
- Boehringer Ingelheim Pharma GmbH & Co. KG
- Boehringer Ingelheim Vetmedica GmbH
- Boeringer Ingelheim Pharma Orient
- CSL Behring GmbH
- European Patent Office
- FUJISAWA GmbH
- Kaesler Nutrition
- Kaesler Nutrition GmbH
- Klifovet A.G.
- Medac GmbH
- Merck KGaA
- MICROMET AG
- Novartis Deutschland GMBH
- ORPHAN EUROPE
- Protagen Protein Services GmbH
- Ratiopharm GmbH
- Roche Diagnostics GmbH
- Sartorius AG
- Sartorius Stedim Biotech GmbH
- Vita 34 AG
Belgium
- BAXTER
- Biosource Europe
- Biotalys
- Elanco Animal Health
- Eurofins Amatsigroup
- EuropaBio
- Galapagos NV
- Glaxo Smithkline Biologicals
- IMEC vzw
- Janssen Pharmaceutica NV
- Omrix Biopharmaceuticals NV/SA
- PhaRA
- SIDLEY AUSTIN LLP
- Total Petrochemicals and Refining SA/NV
- Toxikon Europe N. V
- UCB Pharma SA
- Zoetis Belgium S.A.
Spain
- ALMIRALL
- BioFabri
- C Z Veterinaria S.A.
- Chemo Espana SL
- CZ Veterinaria, S.A
- Dentaid SL
- Digna Biotech SL
- ESTEVE
- Gadea Grupo Farmaceutico
- Laboratorios Leti SL
- Merck SL
- MSD
- Mylan Pharmaceuticals SL
- SCHERING SPAIN SA
Ireland
- Helsinn Birex Pharmaceuticals Ltd
- IDA Ireland
- Irish Patents Office
- MyBio Ltd.
- Pfizer Ireland Pharmaceuticals
- Pfizer Ltd
- Shandon Clinical Trials Limited
- Shire Pharmaceuticals Ireland Limited
- Theravance Biopharma
- Wyeth Biotech
- Wyeth Medica Ireland
United States of America
- ARADIGM CORPORATION
- BD
- Boehringer Ingelheim Pharmaceuticals Inc
- Boehringer Ingelheim Vetmedica Inc
- Hoffmann-La Roche Incorporated
- Medimmune
- MPEG LA
- Pfizer
- Reckitt Benckiser Pharmaceuticals Inc
- Shire
- UCB Inc
Sweden
- APL
- Aros Patent AB
- AstraZeneca
- AstraZeneca AB
- AstraZeneca R & D Sodertalje
- INTERVACC AB
- Q Advance Compliance & Validation AB
- Recipharm AB
- Zacco Sweden AB
Italy
- Bayer Cropscience SRL
- Chiesi Farmaceutical SpA
- chiesi farmaceutici
- Chiesi Farmaceutici S.p.A
- Chiesi Farmaceutici SPA
- Menarini Biotech Srl
- Merck group
- Merck Serono SpA
Saudi Arabia
- ARMED FORCES HOSPITAL
- Hevolution Foundation
- LFSH
- Pharmaceutical safety expert
- Saudi Food and Drug Authority
- The Cooperation Council For The Arab States Of The Gulf
Austria
- Amgen GmbH
- AOP Orphan Pharma
- BIOMIN Holding GmbH
- Boehringer Ingelheim RCV GmbH & Co KG
- Sandoz GmbH
Turkey
- Arven Ilac
- Boehringer Ingelheim Ilaç Tic. A.S.
- Sanovel Pharmaceutical INC
- Turgut Ilac AS
- U.S. Commercial Service Turkey
Finland
- Kolster OY AB
- Medix Biochemica
- Orion Corporation
- Orion Corporation Orion Pharma
Croatia
- Agency for Medicinal Products and Medical Devices of Croatia (HALMED)
- Nicro d.o.o.
- Pliva Croatia Ltd
Poland
- POLPHARMA BIOLOGICS
- Theramex
- Valeant Sp. z o.o. Sp. j.
Australia
- Private Individual
- Specialised Therapeutics Australia Pty Ltd
Egypt
- EGYPTIAN EXPORTERS ASSOCIATION
- EVA PHARMA
Israel
- Elcam Medical Ltd
- Teva Pharmaceutical Industries Ltd
Norway
- ALPHARMA AS
- Bergen Teknologioverforing AS
Portugal
- Industrial Property Portuguese Office
- JABA FARMACEUTICA S.A
Russia
- MOSCOW MEDICAL ACADEMY
- Stada Pharmdevelopment LLC
Slovenia
- Billev farmacija vzhod d.o.o
- LEK Pharmaceuticals d.d.
Canada
- Lifesciences British Columbia
Czech Republic
- Zentiva Group AS
Greece
- NOVO NORDISK AS
Hungary
- Gedeon Richter
Iceland
- Alvotech
India
- Lupin Limited
Indonesia
- Bio Farma
Iran
- Cobel Darou
Malta
- Alvogen Malta Operations ROW
Mexico
- DIAGNOSTICA
Run Biotechnology for the Non-Biotechnologist Classroom/Live online for your team
3 days
Typical duration
Pricing from:
- GBP 1,350
- Per attendee, based on 10 attendees
- Course tailored to your requirements
- At your choice of location, or online
We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.
Contact our in-house training experts Aleksandra Beer and Yesim Nurko to discuss your requirements:
